{"id":10765,"date":"2022-12-01T00:02:55","date_gmt":"2022-11-30T16:02:55","guid":{"rendered":"https:\/\/newsletter.sinica.edu.tw/en\/?p=10765"},"modified":"2024-03-13T09:19:03","modified_gmt":"2024-03-13T01:19:03","slug":"mex3a-mediates-p53-degradation-to-suppress-ferroptosis-and-facilitate-ovarian-cancer-tumorigenesis","status":"publish","type":"post","link":"https:\/\/newsletter.sinica.edu.tw/en\/10765\/","title":{"rendered":"MEX3A mediates p53 degradation to suppress ferroptosis and facilitate ovarian cancer tumorigenesis"},"content":{"rendered":"
Ovarian cancer is a highly heterogeneous and malignant female cancer with an overall low survival rate. In particular, advanced ovarian clear cell carcinoma with wildtype p53 has a poor prognosis, drug resistance, metastasis and recurrence. The research team of Dr. Wendy W. Hwang-Verslues at Genomics Research Center found that MEX3A facilitates p53 degradation to drive ovarian cancer growth by circumventing p53-mediated ferroptosis. These findings suggest that targeting MEX3A can be a potential strategy for treating of ovarian cancer expressing wildtype p53 and were published in Cancer Research<\/em>.<\/p>\n For further information
\nhttps:\/\/www.genomics.sinica.edu.tw\/index.php\/tw\/news\/lastest-news\/701-mex3a-p53<\/a><\/p>\n